US2019231798A1PendingUtilityA1

Compositions and methods for the repair of myelin

Assignee: UNIV DUKEPriority: Jul 9, 2014Filed: Feb 1, 2019Published: Aug 1, 2019
Est. expiryJul 9, 2034(~7.9 yrs left)· nominal 20-yr term from priority
Inventors:Eric J. Benner
A61P 25/28A61P 25/08A61K 35/20A61K 31/575C12N 2506/08C12N 5/0622C12N 2500/36A61P 25/00
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Described are oxysterols, pharmaceutical compositions including the oxysterols, and methods of using the oxysterols and compositions for treating diseases and/or disorders related to myelin injury, such as neonatal brain injury, traumatic brain injury, spinal cord injury, cerebral palsy, seizures, cognitive delay, multiple sclerosis, stroke, autism, leukodystrophy, schizophrenia and bipolar disorder.

Claims

exact text as granted — not AI-modified
1 - 8 . (canceled) 
     
     
         9 . A method of repairing injured myelin in a subject in need thereof, the method comprising administering a therapeutically effect amount of an oxysterol, wherein the injured myelin is associated with spinal cord injury, cerebral palsy, seizures, autism spectrum disorders, cognitive delay, multiple sclerosis, stroke, leukodystrophy, schizophrenia, or bipolar disorder. 
     
     
         10 - 12 . (canceled) 
     
     
         13 . The method of  claim 9 , wherein the oxysterol promotes differentiation of neural stem cells into oligodendrocytes. 
     
     
         14 . The method of  claim 9 , wherein the oxysterol comprises a cholesterol derivative oxidized at any of carbons 20-27. 
     
     
         15 . The method of  claim 9 , wherein the oxysterol is selected from the group consisting of:
 20α-hydroxycholesterol;   22(R)-hydroxycholesterol;   22(S)-hydroxycholesterol;   24(R)-hydroxycholesterol;   24(S)-hydroxycholesterol;   25-hydroxycholesterol; and   27-hydroxycholesterol; or a pharmaceutically acceptable salt thereof.   
     
     
         16 . (canceled) 
     
     
         17 . (canceled) 
     
     
         18 . The method of  claim 9 , wherein the injured myelin is associated with cerebral palsy, autism spectrum disorders, cognitive delay, schizophrenia, or bipolar disorder. 
     
     
         19 . The method of  claim 18 , wherein the injured myelin is associated with cerebral palsy. 
     
     
         20 . The method of  claim 9 , wherein the injured myelin is associated with spinal cord injury, seizures, multiple sclerosis, stroke, or leukodystrophy. 
     
     
         21 . The method of  claim 20 , wherein the injured myelin is associated with multiple sclerosis. 
     
     
         22 . The method of  claim 20 , wherein the injured myelin is a result of spinal cord injury, seizures, multiple sclerosis, stroke, or leukodystrophy. 
     
     
         23 . The method of  claim 22 , wherein the injured myelin is a result of multiple sclerosis.

Join the waitlist — get patent alerts

Track US2019231798A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.